Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, outpatient, crossover study of the anti-platelet effects of AZD6140 [ticagrelor] compared with clopidogrel in patients with stable coronary artery disease previously identified as clopidogrel non-responders or responders [RESPOND].

Next Previous
X
Search
Trial Profile

A randomised, double-blind, outpatient, crossover study of the anti-platelet effects of AZD6140 [ticagrelor] compared with clopidogrel in patients with stable coronary artery disease previously identified as clopidogrel non-responders or responders [RESPOND].

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2012

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ticagrelor (Primary) ; Clopidogrel
  • Indications Coronary artery disease; Embolism and thrombosis
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
  • Acronyms RESPOND

    • Most Recent Events

    • 01 Mar 2010 Results were published online before print March 1 2010.
    • 18 Nov 2009 Results have been presented at the American Heart Association Scientific Sessions (AHA 2009), according to an AstraZeneca media release.
    • 01 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top